Eli Lilly and Company
LLYNext catalyst
Abemaciclib
Breast Cancer
Get an email about LLY's next catalysts
Track Eli Lilly and Company (LLY) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
Plus 28 more upcoming events in our data (Phase 2 readout, company event, Phase 3 readout).See the timeline
29 upcoming, 5 past
Abemaciclib Phase 2 Est. Readout
Estimated primary completion for Abemaciclib trial (NCT04393285) in Endometrial Cancer. Topline data typically follows completion by weeks to months.
SourceNecitumumab Phase 2 Est. Readout
Estimated primary completion for Necitumumab trial (NCT04285671) in Metastatic Lung Non-Small Cell Carcinoma. Topline data typically follows completion by weeks to months.
SourceCetuximab, Cisplatin, Doxorubicin & Cyclophosphamide Phase 2 Est. Readout
Estimated primary completion for Cetuximab, Cisplatin, Doxorubicin & Cyclophosphamide trial (NCT01025089) in Thymoma. Topline data typically follows completion by weeks to months.
SourceOther
Centessa Pharmaceuticals announced a CEO transition with president Mario Alberto Accardi set to assume the top role on January 1, 2027, replacing Saurabh Saha. The company is also appointing a new CMO for a cardiovascular program led by John Maraganore and Clive Meanwell.
Brenipatide Phase 2 Est. Readout (RENEW-Smk-1)
Primary completion for Brenipatide trial (NCT07223840) in Smoking
SourcePirtobrutinib Phase 2 Est. Readout
Estimated primary completion for Pirtobrutinib trial (NCT06522386) in Mantle Cell Lymphoma. Topline data typically follows completion by weeks to months.
SourceSolbinsiran Phase 2 Est. Readout (SOLARIS-1)
Estimated primary completion for Solbinsiran trial (NCT07269210) in Severe Hypertriglyceridemia. Topline data typically follows completion by weeks to months.
SourceNiraparib Tosylate Monohydrate Phase 2 Est. Readout (NICHOL)
Estimated primary completion for Niraparib Tosylate Monohydrate trial (NCT06594679) in Ovarian Cancer. Topline data typically follows completion by weeks to months.
SourceHow LLY's past catalysts played out
Market Overview
Stock performance and key metrics
Eli Lilly and Company, doing business as Lilly, is an American multinational pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries. The company was founded in 1876 by Eli Lilly, a pharmaceutical chemist and Union army veteran during the American Civil War for whom the company was later named.
WebsiteRemternetug (SC)
Alzheimer's Disease
Retatrutide
Obesity
Ultra-Rapid Lispro
Type 1 Diabetes Mellitus
LY2216684
Major Depressive Disorder
Insulin Efsitora Alfa
Type 2 Diabetes
Abemaciclib
Breast Cancer
LY3819253
COVID-19
LY900014
Type 1 Diabetes Mellitus
Ixekizumab Auto-Injector
Plaque Psoriasis
GEMZAR
Pancreatic Neoplasms
Dulaglutide
Type 2 Diabetes Mellitus
LY2605541
Type 1 Diabetes Mellitus
Baricitinib
Systemic Juvenile Idiopathic Arthritis
Galcanezumab
Chronic Migraine
Ixekizumab
Psoriasis
Tirzepatide
Overweight
Remternetug (IV)
Alzheimer's Disease
LY353381
Breast Neoplasms
Insulin Peglispro
Type 2 Diabetes Mellitus
teriparatide
Osteoporosis, Postmenopausal
Insulin Lispro
Type 2 Diabetes Mellitus
Paclitaxel (Taxane)
Non-Small-Cell Lung Carcinoma
Human Insulin Inhalation Powder
Diabetes Mellitus, Type 2
Detemir
Diabetes Mellitus Type 2
tadalafil once a day [T(OaD)]
Erectile Dysfunction
Etanercept
Plaque Psoriasis
Insulin Degludec
Type 2 Diabetes Mellitus
Insulin lispro mix 25
Diabetes Mellitus Type 2
cDMARD
Rheumatoid Arthritis
LY2963016
Type 1 Diabetes
[Lu-177]-PNT2002
Metastatic Castration-Resistant Prostate Cancer
LY2062430
Alzheimer's Disease
liposomal doxorubicin
Genital Neoplasms, Female
BEC2 Vaccine
Carcinoma, Small Cell Lung
Lebrikizumab
Atopic Dermatitis
LY3537982
Carcinoma, Non-Small-Cell Lung
amantadine
Schizophrenia
venlafaxine
Anxiety Disorders
Necitumumab
Solid Tumors
enzastaurin
Non-Small Cell Lung Cancer
Tadalafil
Benign Prostatic Hyperplasia
Methylphenidate
Attention Deficit Hyperactivity Disorder
Glargine
Diabetes Mellitus, Type 1
lithium
Manic or Mixed Episode Associated With Bipolar I Disorder
Donanemab
Alzheimer Disease
Imlunestrant
Breast Neoplasms
Insulin Lispro Protamine Suspension
Diabetes Mellitus, Type 2
Somatropin
Growth Hormone Deficiency
Nasal Glucagon
Hypoglycemia
Lasmiditan
Migraine
Oral antihyperglycemics
Diabetes Mellitus
BI 10773/BI 1356
Diabetes Mellitus, Type 2
Raloxifene
Vasomotor Symptoms
Tirzepatide Dose 1
Type2 Diabetes
Intramuscular Glucagon
Diabetes Mellitus, Type 1
Oral Antihyperglycemic Medications (OAMs)
Type 2 Diabetes Mellitus
Insulin Lispro 6 Day (6D)
Diabetes Mellitus, Type 1
Remternetug
Alzheimer's Disease
Fluoxetine
Major Depressive Disorder
Orforglipron
Obesity
Methylphenidate Hydrochloride
Attention Deficit Hyperactivity Disorder
gemcitabine hydrochloride
Breast Cancer
Insulin Lispro Protamine Suspension (ILPS)
Diabetes Mellitus, Type 2
Human Insulin NPH
Diabetes Mellitus, Type 2
Drotrecogin alfa (activated)
Sepsis
Salmon Calcitonin
Osteoporosis
LY3537031
Alcohol Use Disorder
Risedronate
Osteoporosis
LY4064809
Breast Neoplasms
Topical corticosteroid
Atopic Dermatitis
Olomorasib
Carcinoma, Non-Small-Cell Lung
Insulin lispro 2 day reservoir in-use
Diabetes Mellitus, Type 1
teriparatide 20 micrograms/day subcutaneous
Osteoporosis, Post-Menopausal
Nasal Glucagon (NG)
Drug-specific Antibodies
Standard therapy for INCS
Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
Lantus
Diabetes Mellitus, Type 2
Neutral protamine hagedorn insulin
Diabetes Mellitus, Type 2
Ethinyl estradiol
Turner Syndrome
dirucotide
Secondary Progressive Multiple Sclerosis
Insulin Aspart
Type 2 Diabetes Mellitus
Ramucirumab DP (IMC-1121B)
Hepatocellular Carcinoma
Injectable insulin
Diabetes Mellitus, Type 2
ixekizumab Dosing Regimen
Psoriasis
SSRI
Major Depressive Disorder
leuprorelin
Idiopathic Short Stature (ISS)
Sofetabart Mipitecan
Ovarian Neoplasms
Atomoxetine
Attention Deficit Hyperactivity Disorder
Pemetrexed
Non-small Cell Lung Cancer
Somatropin (rDNA origin) for injection
Failure to Thrive
LY3650150
Perennial Allergic Rhinitis (PAR)
LY2189265
Diabetes Mellitus, Type 2
Sulfonylureas (SU)
Type 2 Diabetes Mellitus
LY2127399
Arthritis, Rheumatoid
Testosterone Solution
Hypogonadism
Folinic acid
Colorectal Carcinoma
Arzoxifene
Osteoporosis, Postmenopausal
Mirikizumab
Ulcerative Colitis
Etesevimab
COVID-19
Human regular U-500 insulin (CSII)
Type 2 Diabetes Mellitus
Tanezumab
Osteoarthritis, Hip
Oral Antihyperglycemic Medication
Diabetes Mellitus, Type 2
Intramuscular olanzapine depot
Schizophrenic Disorders
Pegilodecakin
Pancreatic Cancer
Secukinumab
Psoriasis
LY900003
Carcinoma, Non-Small-Cell Lung
Paroxetine
Major Depressive Disorder
Galunisertib
Glioblastoma
Humalog Mix 50
Diabetes Mellitus, Type 1
Aducanumab
Mild Cognitive Impairment (MCI)
LY2216684 (edivoxetine)
Depressive Disorder, Major
simplified diabetes regimen starting with a fixed dose of Human Insulin Inhalation Powder
Diabetes Mellitus, Type 2
Rapid-Acting Intramuscular Olanzapine
Schizophrenia
Biguanides (BG)
Type 2 Diabetes Mellitus
Exenatide
Diabetes Mellitus, Type 2
Biguanide (BG)
Type 2 Diabetes Mellitus
semagacestat
Alzheimer's Disease
LY450139
Alzheimer's Disease
Vepugratinib
Carcinoma, Transitional Cell
LANTUS®
Diabetes Mellitus, Type 2
SGLT2 inhibitor
Type 2 Diabetes Mellitus
Ruboxistaurin mesylate
Diabetic Neuropathies
solanezumab
Alzheimer's Disease
Finasteride
Benign Prostatic Hyperplasia
Glucagon Nasal Powder
Diabetes Mellitus
Standard Adjuvant Endocrine Therapy
Breast Cancer
Alendronate Sodium
Osteoporosis
Oral antihyperglycemic medication (OAM)
Type 2 Diabetes Mellitus
Muvalaplin
Elevated Lp(a)
Tamsulosin
Benign Prostatic Hyperplasia
Ixekizumab Dosing Regimens 1, 2, and 3
Psoriasis
insulin lispro injection Low Mix
Type 2 Diabetes Mellitus
Ramucirumab (IMC-1211B) DP
Gastric Cancer
Prasugrel
Sickle Cell Anemia
Commercially-available Aspirin
Acute Coronary Syndrome
Lepodisiran Sodium
Atherosclerotic Cardiovascular Disease (ASCVD)
Fumaric Acid Esters
Plaque Psoriasis
Testosterone MD-Lotion
Hypogonadism
Raloxifene HCL
Osteoporosis, Postmenopausal
Calcium Supplement
Osteoporosis, Postmenopausal
Eloralintide
Overweight
Duloxetine Hydrochloride (HCI)
Multiple Sclerosis
somatropin, rDNA origin, for injection
Growth Disorder
OAMs
Diabetes Mellitus, Type 2
salmon calcitonin subcutaneous
Osteoporosis, Post-Menopausal
Ramucirumab (IMC-1121B)
Breast Cancer
Lebrikizumab Pen
Atopic Dermatitis
5-Fluorouracil
Head and Neck Cancer
Cetuximab
Ovarian Cancer
Selpercatinib
Non-Small Cell Lung Cancer
ERA as specific PAH treatment
Hypertension, Pulmonary
Escitalopram
Major Depressive Disorder
Haloperidol
Schizophrenia
Mirikizumab SC
Ulcerative Colitis
Insulin Lispro (U100)
Type 2 Diabetes
Duloxetine hydrochloride
Diabetic Neuropathy, Painful
injected insulin
Diabetes Mellitus
Ruboxistaurin
Type 1 Diabetes Mellitus
Olanzapine and Fluoxetine combination (OFC)
Treatment Resistant Depression
high dose FDC
Diabetes Mellitus, Type 2
Brenipatide
Asthma
BI 10773 low dose
Diabetes Mellitus, Type 2
low dose FDC
Diabetes Mellitus, Type 2
calcitonin subcutaneous
Osteoporosis, Post-Menopausal
cleminorexton
Narcolepsy Type 1
Insulin Levemir
Diabetes Mellitus, Type 1
Bamlanivimab
COVID-19
Mirikizumab IV
Ulcerative Colitis
Olaratumab
Metastatic Pancreatic Cancer
Pirtobrutinib
Lymphoma, Non-Hodgkin
Olanzapine Hydrochloride
Bipolar Disorder
Other standard therapy for ADHD
Attention Deficit Hyperactivity Disorder
Linagliptin/Pioglitazone FDC
Diabetes Mellitus, Type 2
Lepodisiran
Atherosclerosis
BI 10773
Diabetes Mellitus, Type 2
TAS 102
Colorectal Cancer
Linagliptin
Diabetes Mellitus, Type 2
Intracoronary infusion of enriched bone marrow-derived progenitor cells
Myocardial Infarction
Sulfonylureas
Type 2 Diabetes Mellitus
Docetaxel (Taxane)
Non-Small-Cell Lung Carcinoma
valproate
Manic or Mixed Episode Associated With Bipolar I Disorder
Insulin lispro 6 day reservoir in-use
Diabetes Mellitus, Type 1
alpha-glucosidase inhibitor (a-GI)
Type 2 Diabetes Mellitus
Empagliflozin low dose qd
Diabetes Mellitus, Type 2
Glinides
Type 2 Diabetes Mellitus
Empagliflozin low dose bid
Diabetes Mellitus, Type 2
fibrinolytic therapy or combination reduced fibrinolytic therapy
Myocardial Infarction
Empagliflozin high dose qd
Diabetes Mellitus, Type 2
Empagliflozin high dose bid
Diabetes Mellitus, Type 2
Topical Corticosteroid (TCS)
Atopic Dermatitis
Empagliflozin + Linagliptin
Diabetes Mellitus, Type 2
BI 10773 open label
Diabetes Mellitus, Type 2
BI10773
Diabetes Mellitus, Type 2
Ixekizumab Prefilled Syringe
Plaque Psoriasis
Atomoxetine Hydrochloride
Attention Deficit Hyperactivity Disorder
Erbitux (Cetuximab)
Colorectal Neoplasms
LY3295668
Neoplasms
LY2523355
Metastatic Breast Cancer
Sivelestat
Respiratory Distress Syndrome, Adult
Icrucumab
Colon Cancer
LY2140023
Schizophrenia
LY3209590
Type 2 Diabetes Mellitus
Empagliflozin low
Diabetes Mellitus, Type 1
cetuximab (Erbitux ®)
Head and Neck Cancer
Herceptin
Breast Cancer
Enzastaurin Hydrochloride
Breast Neoplasms
Pemetrexed - Phase 1
Ovarian Cancer
IMC-1121B (ramucirumab)
Carcinoma, Non-Small-Cell Lung
LY3041658
Hidradenitis Suppurativa
Ipatasertib
Endometrial Cancer
LY4268989
Ulcerative Colitis
LY4100511
Plaque Psoriasis
Inavolisib
Endometrial Cancer
Pemetrexed - Before Protocol Amendment
Non Small Cell Lung Cancer
LY3016859
Osteoarthritis
LY2484595
Dyslipidemia
MORF-057
Inflammatory Bowel Diseases
DC-806
Plaque Psoriasis
Carboplatin, Pemetrexed and Bevacizumab
Non Small Cell Lung Cancer
Granulocyte colony-stimulating factor (G-CSF)
Small Cell Lung Cancer
Prexasertib
Ovarian Cancer
LY2409021
Diabetes Mellitus, Type 2
avastin
Colorectal Cancer
Hydroxychloroquine Sulfate
Pancreatic Cancer
LY3473329
Lipoprotein Disorder
LY517717
Total Knee Replacement
LY3857210
Diabetic Peripheral Neuropathic Pain
LY2951742
Migraine Headache
Enzyme-inducing antiepileptic drugs (EIAED)
Recurrent Glioblastoma
Cixutumumab
Non-Small-Cell Lung Carcinoma
Mitoxantrone
Prostate Cancer
Folate
Non-small Cell Lung Cancer (NSCLC)
LY4005130
Vitiligo
Carboplatin (AUC 6)
Carcinoma, Non-Small-Cell Lung
LY4395089
Crohn Disease
LY2189102
Arthritis, Rheumatoid
Doxorubicin (Adriamycin)
Hodgkin's Disease
LY3451838
Migraine
Taltz
Idiopathic Subglottic Stenosis
Non-enzyme inducing antiepileptic drugs (NEIAED)
Recurrent Glioblastoma
LY2422347
Sleep Initiation and Maintenance Disorders
Platinol
Carcinoma, Transitional Cell
LY4065967
Diabetic Peripheral Neuropathic Pain
LY2623091
Primary Hypertension
LY3938577
Diabetes Mellitus, Type 2
Mirikizumab - Intravenous (IV)
Crohn Disease
LY2428757
Diabetes Mellitus, Type 2
LOXO-292
Medullary Thyroid Cancer
Tadalafil- Tablet or Oral suspension
Pulmonary Arterial Hypertension
LY3023414
Prostate Cancer Metastatic
Pemetrexed - After Protocol Amendment
Non Small Cell Lung Cancer
Enzastaurin HCL
Non-Small-Cell Lung Carcinoma
IMC-A12
Prostate Cancer
Mirikizumab - Subcutaneous (SC)
Crohn Disease
LY3561774
Dyslipidemias
LY3848575
Neuropathic Pain
Mevidalen
Alzheimer Disease
ALIMTA
Colorectal Cancer
Bimagrumab
Obesity
LY2603618
Non Small Cell Lung Cancer
BI 10773 high dose
Diabetes Mellitus, Type 2
LY2439821
Rheumatoid Arthritis
human insulin inhalation powder (HIIP)
Diabetes Mellitus, Type 1
LY3457263
Type 2 Diabetes
Emibetuzumab
Carcinoma, Non-Small-Cell Lung
Testosterone
Ejaculatory Dysfunction
LY3214996
Pancreatic Cancer
Solbinsiran
Severe Hypertriglyceridemia
Cetuximab + platinum + gemcitabine
Non-Small-Cell Lung Carcinoma
Prophylactic Loperamide
Metastatic Breast Cancer
Dinutuximab
Relapsed Solid Tumor
Ramucirumab DP
Carcinoma of Urinary Tract
LY451395
Alzheimer's Disease
Cetuximab, Cisplatin, Doxorubicin & Cyclophosphamide
Thymoma
LY3016859 ISA
Osteoarthritis, Knee
LOXO-305
Leukemia, Lymphoid
LY317615
Non-Hodgkin's Lymphoma
LY2181308 sodium
Prostate Cancer
LY3819469
Lipoprotein Disorder
LY686017
Social Phobia
LY573636-sodium
Ovarian Cancer
Zagotenemab
Alzheimer Disease (AD)
Enzastaurin 500 milligram (mg) Once Daily (QD)
Glioblastoma Multiforme
STX-478
Breast Cancer
naveglitazar
Diabetes Mellitus, Non-Insulin-Dependent
Mazdutide
Alcohol Use Disorder
Macupatide
Obesity
LY2452473
Erectile Dysfunction
LY3305677
Obesity
LY2875358
Carcinoma, Non-Small-Cell Lung
LY450139 dihydrate
Alzheimer's Disease
Merestinib
Biliary Tract Cancer
Pemetrexed (Alimta) in combination with gemcitabine (Gemzar)
Carcinoma, Non-Small-Cell Lung
IMC-11F8 (necitumumab)
Metastatic Colorectal Cancer
U-500 insulin, 200 syringe units
Type 2 Diabetes
LY2196044
Alcohol Dependence
LY3009104
Arthritis, Rheumatoid
Drotrecogin alfa activated (Xigris)
End Stage Renal Disease
Baricitinib 4 milligram Oral Tablet
Lichen Planus, Oral
IMC-A12 (Cixutumumab)
Adenocarcinoma of the Prostate
LY2090314
Leukemia
Eltrekibart
Hidradenitis Suppurativa
Lutetium Lu 177-PSMA-617
Castration-Resistant Prostate Carcinoma
5FU/folinic acid
Colorectal Cancer
Empagliflozin medium
Diabetes Mellitus, Type 1
LY3541860
Rheumatoid Arthritis
5 - Fluorouracil
Solid Tumor
Leucovorin (LV)
Colorectal Cancer
Pemetrexed Phase 1
Non-Small Cell Lung Cancer
LY3537021
Nausea
Lutetium Lu-177 PNT2002
Oligometastatic Prostate Carcinoma
LY3462817
Rheumatoid Arthritis
Exenatide/min
Euglycemia
carboplatin and gemcitabine
Non Small Cell Lung Cancer
LY3015014
Hypercholesterolemia
LY2624803
Primary Insomnia
Vitamin B12
Non Small Cell Lung Cancer
LY041001 (HIIP)
Diabetes Mellitus, Type 2
IMC-A12 (cixutumumab) - 10 milligrams/kilogram (mg/kg)
Hepatocellular Carcinoma
Mibavademab
Obesity
LY3972406
Plaque Psoriasis
LY3372689
Alzheimer Disease
Selpercatinib Monotherapy
Differentiated Thyroid Cancer
Empagliflozin high
Diabetes Mellitus, Type 1
Carboplatin - Phase 2
Ovarian Cancer
LY3841136
Obesity
Gemcitabine, Etoposide
Pancreatic Cancer
LY3039478
T-cell Acute Lymphoblastic Leukemia
LY3437943
Obesity
LY2510924
Extensive Stage Small Cell Lung Carcinoma
ORX750
Narcolepsy Type 1
LY293111
Pancreatic Cancer
LY2828360
Osteoarthritis, Knee
LY3023703
Acute Pain
pegfilgrastim
Ovarian Cancer
LY2189265 and Lifestyle Measures
Diabetes Mellitus, Type 2
Cetuximab in combination with Carboplatin/Gemcitabine
Stage IV Non-Small Cell Lung Cancer
LY518674
Metabolic Syndrome X
Prasugrel (CS-747)
Cardiovascular Diseases
sPLA2 Inhibitor
Sepsis
LY3526318
Chronic Low-back Pain
Mazisotine
Diabetic Peripheral Neuropathy
LY2495655
Pancreatic Cancer
U-500 insulin, 100 syringe units
Type 2 Diabetes
IMC-1121B
Cancer
Transdermal Teriparatide
Osteoporosis
Galcanezumab Prefilled Syringe
Vestibular Migraine
Carboplatin - Phase 1
Ovarian Cancer
LY3202626
Alzheimer Disease
IMC-18F1
Breast Cancer
PPAR alpha
Hypercholesterolemia
5 - FU
Solid Tumor
Folinic acid (FA)
Metastatic Colorectal Cancer
gemcitabine, folinic acid, 5-FU
Metastatic Pancreatic Cancer
Buprenorphine
Opioid Use Disorder
LY3549492
Obesity
LY3154207
Lewy Body Dementia
Niraparib Tosylate Monohydrate
Ovarian Cancer
arzoxifene hydrochloride
Endometrial Cancer
Eplerenone
Chronic Kidney Disease
Triamcinolone (Optional)
Atopic Dermatitis
depot octreotide
Carcinoma
Subcutaneous Teriparatide
Osteoporosis
LY3556050
Diabetic Peripheral Neuropathy
Pemetrexed - Phase 2
Ovarian Cancer
ALIMTA plus Epirubicin
Breast Cancer
Fulvestrant Run-In
ER-Positive Breast Cancer
LY3871801
Rheumatoid Arthritis
LY2157299
Hepatocellular Carcinoma
LY2181308
Non-small Cell Lung Cancer
tasisulam
Metastatic Melanoma
Giredestrant
Endometrial Cancer
LY2784544
Neoplasms, Hematologic
LY3502970
Obesity
LY2541546
Osteoporosis
S-1
Metastatic Gastric Adenocarcinoma
LY2228820
Epithelial Ovarian Cancer
mitomycin C
Superficial Bladder Cancer
empagliflozin low dose
Diabetes Mellitus, Type 1
LY545694
Osteoarthritis Knee Pain
empagliflozin medium dose
Diabetes Mellitus, Type 1
Brexucabtagene Autoleucel
Mantle Cell Lymphoma
empagliflozin high dose
Diabetes Mellitus, Type 1
Platinum + Gemcitabine
Non-Small-Cell Lung Carcinoma
Radiation
Glioma
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Remternetug (SC) | Phase 3 | Alzheimer's Disease | - | - |
Retatrutide | Phase 3 | Obesity | - | - |
Ultra-Rapid Lispro | Phase 3 | Type 1 Diabetes Mellitus | - | - |
LY2216684 | Phase 3 | Major Depressive Disorder | - | - |
Insulin Efsitora Alfa | Phase 3 | Type 2 Diabetes | - | - |
Abemaciclib | Phase 3 | Breast Cancer | - | Patent 2039 |
LY3819253 | Phase 3 | COVID-19 | - | - |
LY900014 | Phase 3 | Type 1 Diabetes Mellitus | - | - |
Ixekizumab Auto-Injector | Phase 3 | Plaque Psoriasis | - | - |
GEMZAR | Phase 3 | Pancreatic Neoplasms | - | - |
Dulaglutide | Phase 3 | Type 2 Diabetes Mellitus | - | - |
LY2605541 | Phase 3 | Type 1 Diabetes Mellitus | - | - |
Baricitinib | Phase 3 | Systemic Juvenile Idiopathic Arthritis | - | Patent 2032 |
Galcanezumab | Phase 3 | Chronic Migraine | - | - |
Ixekizumab | Phase 3 | Psoriasis | - | - |
Tirzepatide | Phase 3 | Overweight | - | Patent 2041 |
Remternetug (IV) | Phase 3 | Alzheimer's Disease | - | - |
LY353381 | Phase 3 | Breast Neoplasms | - | - |
Insulin Peglispro | Phase 3 | Type 2 Diabetes Mellitus | - | - |
teriparatide | Phase 3 | Osteoporosis, Postmenopausal | - | |
Insulin Lispro | Phase 3 | Type 2 Diabetes Mellitus | - | - |
Paclitaxel (Taxane) | Phase 3 | Non-Small-Cell Lung Carcinoma | - | Patent 2034 |
Human Insulin Inhalation Powder | Phase 3 | Diabetes Mellitus, Type 2 | - | - |
Detemir | Phase 3 | Diabetes Mellitus Type 2 | - | - |
tadalafil once a day [T(OaD)] | Phase 3 | Erectile Dysfunction | - | - |
Etanercept | Phase 3 | Plaque Psoriasis | - | - |
Insulin Degludec | Phase 3 | Type 2 Diabetes Mellitus | - | - |
Insulin lispro mix 25 | Phase 3 | Diabetes Mellitus Type 2 | - | - |
cDMARD | Phase 3 | Rheumatoid Arthritis | - | - |
LY2963016 | Phase 3 | Type 1 Diabetes | - | - |
[Lu-177]-PNT2002 | Phase 3 | Metastatic Castration-Resistant Prostate Cancer | - | - |
LY2062430 | Phase 3 | Alzheimer's Disease | - | - |
liposomal doxorubicin | Phase 3 | Genital Neoplasms, Female | - | - |
BEC2 Vaccine | Phase 3 | Carcinoma, Small Cell Lung | - | - |
Lebrikizumab | Phase 3 | Atopic Dermatitis | - | - |
LY3537982 | Phase 3 | Carcinoma, Non-Small-Cell Lung | - | - |
amantadine | Phase 3 | Schizophrenia | - | - |
venlafaxine | Phase 3 | Anxiety Disorders | - | - |
Necitumumab | Phase 3 | Solid Tumors | - | - |
enzastaurin | Phase 3 | Non-Small Cell Lung Cancer | - | - |
Tadalafil | Phase 3 | Benign Prostatic Hyperplasia | - | - |
Methylphenidate | Phase 3 | Attention Deficit Hyperactivity Disorder | - | - |
Glargine | Phase 3 | Diabetes Mellitus, Type 1 | - | - |
lithium | Phase 3 | Manic or Mixed Episode Associated With Bipolar I Disorder | - | - |
Donanemab | Phase 3 | Alzheimer Disease | - | - |
Imlunestrant | Phase 3 | Breast Neoplasms | - | - |
Insulin Lispro Protamine Suspension | Phase 3 | Diabetes Mellitus, Type 2 | - | - |
Somatropin | Phase 3 | Growth Hormone Deficiency | - | - |
Nasal Glucagon | Phase 3 | Hypoglycemia | - | - |
Lasmiditan | Phase 3 | Migraine | - | - |
Oral antihyperglycemics | Phase 3 | Diabetes Mellitus | - | - |
BI 10773/BI 1356 | Phase 3 | Diabetes Mellitus, Type 2 | - | - |
Raloxifene | Phase 3 | Vasomotor Symptoms | - | - |
Tirzepatide Dose 1 | Phase 3 | Type2 Diabetes | - | - |
Intramuscular Glucagon | Phase 3 | Diabetes Mellitus, Type 1 | - | - |
Oral Antihyperglycemic Medications (OAMs) | Phase 3 | Type 2 Diabetes Mellitus | - | - |
Insulin Lispro 6 Day (6D) | Phase 3 | Diabetes Mellitus, Type 1 | - | - |
Remternetug | Phase 3 | Alzheimer's Disease | - | - |
Fluoxetine | Phase 3 | Major Depressive Disorder | - | - |
Orforglipron | Phase 3 | Obesity | - | - |
Methylphenidate Hydrochloride | Phase 3 | Attention Deficit Hyperactivity Disorder | - | - |
gemcitabine hydrochloride | Phase 3 | Breast Cancer | - | - |
Insulin Lispro Protamine Suspension (ILPS) | Phase 3 | Diabetes Mellitus, Type 2 | - | - |
Human Insulin NPH | Phase 3 | Diabetes Mellitus, Type 2 | - | - |
Drotrecogin alfa (activated) | Phase 3 | Sepsis | - | - |
Salmon Calcitonin | Phase 3 | Osteoporosis | - | - |
LY3537031 | Phase 3 | Alcohol Use Disorder | - | - |
Risedronate | Phase 3 | Osteoporosis | - | - |
LY4064809 | Phase 3 | Breast Neoplasms | - | - |
Topical corticosteroid | Phase 3 | Atopic Dermatitis | - | - |
Olomorasib | Phase 3 | Carcinoma, Non-Small-Cell Lung | - | - |
Insulin lispro 2 day reservoir in-use | Phase 3 | Diabetes Mellitus, Type 1 | - | - |
teriparatide 20 micrograms/day subcutaneous | Phase 3 | Osteoporosis, Post-Menopausal | - | - |
Nasal Glucagon (NG) | Phase 3 | Drug-specific Antibodies | - | - |
Standard therapy for INCS | Phase 3 | Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) | - | - |
Lantus | Phase 3 | Diabetes Mellitus, Type 2 | - | - |
Neutral protamine hagedorn insulin | Phase 3 | Diabetes Mellitus, Type 2 | - | - |
Ethinyl estradiol | Phase 3 | Turner Syndrome | - | - |
dirucotide | Phase 3 | Secondary Progressive Multiple Sclerosis | - | - |
Insulin Aspart | Phase 3 | Type 2 Diabetes Mellitus | - | - |
Ramucirumab DP (IMC-1121B) | Phase 3 | Hepatocellular Carcinoma | - | - |
Injectable insulin | Phase 3 | Diabetes Mellitus, Type 2 | - | - |
ixekizumab Dosing Regimen | Phase 3 | Psoriasis | - | - |
SSRI | Phase 3 | Major Depressive Disorder | - | - |
leuprorelin | Phase 3 | Idiopathic Short Stature (ISS) | - | - |
Sofetabart Mipitecan | Phase 3 | Ovarian Neoplasms | - | - |
Atomoxetine | Phase 3 | Attention Deficit Hyperactivity Disorder | - | - |
Pemetrexed | Phase 3 | Non-small Cell Lung Cancer | - | - |
Somatropin (rDNA origin) for injection | Phase 3 | Failure to Thrive | - | - |
LY3650150 | Phase 3 | Perennial Allergic Rhinitis (PAR) | - | - |
LY2189265 | Phase 3 | Diabetes Mellitus, Type 2 | - | - |
Sulfonylureas (SU) | Phase 3 | Type 2 Diabetes Mellitus | - | - |
LY2127399 | Phase 3 | Arthritis, Rheumatoid | - | - |
Testosterone Solution | Phase 3 | Hypogonadism | - | - |
Folinic acid | Phase 3 | Colorectal Carcinoma | - | - |
Arzoxifene | Phase 3 | Osteoporosis, Postmenopausal | - | - |
Mirikizumab | Phase 3 | Ulcerative Colitis | - | - |
Etesevimab | Phase 3 | COVID-19 | - | - |
Human regular U-500 insulin (CSII) | Phase 3 | Type 2 Diabetes Mellitus | - | - |
Tanezumab | Phase 3 | Osteoarthritis, Hip | - | - |
Oral Antihyperglycemic Medication | Phase 3 | Diabetes Mellitus, Type 2 | - | - |
Intramuscular olanzapine depot | Phase 3 | Schizophrenic Disorders | - | - |
Pegilodecakin | Phase 3 | Pancreatic Cancer | - | - |
Secukinumab | Phase 3 | Psoriasis | - | - |
LY900003 | Phase 3 | Carcinoma, Non-Small-Cell Lung | - | - |
Paroxetine | Phase 3 | Major Depressive Disorder | - | - |
Galunisertib | Phase 3 | Glioblastoma | - | - |
Humalog Mix 50 | Phase 3 | Diabetes Mellitus, Type 1 | - | - |
Aducanumab | Phase 3 | Mild Cognitive Impairment (MCI) | - | - |
LY2216684 (edivoxetine) | Phase 3 | Depressive Disorder, Major | - | - |
simplified diabetes regimen starting with a fixed dose of Human Insulin Inhalation Powder | Phase 3 | Diabetes Mellitus, Type 2 | - | - |
Rapid-Acting Intramuscular Olanzapine | Phase 3 | Schizophrenia | - | - |
Biguanides (BG) | Phase 3 | Type 2 Diabetes Mellitus | - | - |
Exenatide | Phase 3 | Diabetes Mellitus, Type 2 | - | - |
Biguanide (BG) | Phase 3 | Type 2 Diabetes Mellitus | - | - |
semagacestat | Phase 3 | Alzheimer's Disease | - | - |
LY450139 | Phase 3 | Alzheimer's Disease | - | - |
Vepugratinib | Phase 3 | Carcinoma, Transitional Cell | - | - |
LANTUS® | Phase 3 | Diabetes Mellitus, Type 2 | - | - |
SGLT2 inhibitor | Phase 3 | Type 2 Diabetes Mellitus | - | - |
Ruboxistaurin mesylate | Phase 3 | Diabetic Neuropathies | - | - |
solanezumab | Phase 3 | Alzheimer's Disease | - | - |
Finasteride | Phase 3 | Benign Prostatic Hyperplasia | - | - |
Glucagon Nasal Powder | Phase 3 | Diabetes Mellitus | - | - |
Standard Adjuvant Endocrine Therapy | Phase 3 | Breast Cancer | - | - |
Alendronate Sodium | Phase 3 | Osteoporosis | - | - |
Oral antihyperglycemic medication (OAM) | Phase 3 | Type 2 Diabetes Mellitus | - | - |
Muvalaplin | Phase 3 | Elevated Lp(a) | - | - |
Tamsulosin | Phase 3 | Benign Prostatic Hyperplasia | - | - |
Ixekizumab Dosing Regimens 1, 2, and 3 | Phase 3 | Psoriasis | - | - |
insulin lispro injection Low Mix | Phase 3 | Type 2 Diabetes Mellitus | - | - |
Ramucirumab (IMC-1211B) DP | Phase 3 | Gastric Cancer | - | - |
Prasugrel | Phase 3 | Sickle Cell Anemia | - | - |
Commercially-available Aspirin | Phase 3 | Acute Coronary Syndrome | - | - |
Lepodisiran Sodium | Phase 3 | Atherosclerotic Cardiovascular Disease (ASCVD) | - | - |
Fumaric Acid Esters | Phase 3 | Plaque Psoriasis | - | - |
Testosterone MD-Lotion | Phase 3 | Hypogonadism | - | - |
Raloxifene HCL | Phase 3 | Osteoporosis, Postmenopausal | - | - |
Calcium Supplement | Phase 3 | Osteoporosis, Postmenopausal | - | - |
Eloralintide | Phase 3 | Overweight | - | - |
Duloxetine Hydrochloride (HCI) | Phase 3 | Multiple Sclerosis | - | - |
somatropin, rDNA origin, for injection | Phase 3 | Growth Disorder | - | - |
OAMs | Phase 3 | Diabetes Mellitus, Type 2 | - | - |
salmon calcitonin subcutaneous | Phase 3 | Osteoporosis, Post-Menopausal | - | - |
Ramucirumab (IMC-1121B) | Phase 3 | Breast Cancer | - | - |
Lebrikizumab Pen | Phase 3 | Atopic Dermatitis | - | - |
5-Fluorouracil | Phase 3 | Head and Neck Cancer | - | - |
Cetuximab | Phase 3 | Ovarian Cancer | - | - |
Selpercatinib | Phase 3 | Non-Small Cell Lung Cancer | - | - |
ERA as specific PAH treatment | Phase 3 | Hypertension, Pulmonary | - | - |
Escitalopram | Phase 3 | Major Depressive Disorder | - | - |
Haloperidol | Phase 3 | Schizophrenia | - | - |
Mirikizumab SC | Phase 3 | Ulcerative Colitis | - | - |
Insulin Lispro (U100) | Phase 3 | Type 2 Diabetes | - | - |
Duloxetine hydrochloride | Phase 3 | Diabetic Neuropathy, Painful | - | - |
injected insulin | Phase 3 | Diabetes Mellitus | - | - |
Ruboxistaurin | Phase 3 | Type 1 Diabetes Mellitus | - | - |
Olanzapine and Fluoxetine combination (OFC) | Phase 3 | Treatment Resistant Depression | - | - |
high dose FDC | Phase 3 | Diabetes Mellitus, Type 2 | - | - |
Brenipatide | Phase 3 | Asthma | - | - |
BI 10773 low dose | Phase 3 | Diabetes Mellitus, Type 2 | - | - |
low dose FDC | Phase 3 | Diabetes Mellitus, Type 2 | - | - |
calcitonin subcutaneous | Phase 3 | Osteoporosis, Post-Menopausal | - | - |
cleminorexton | Phase 3 | Narcolepsy Type 1 | - | - |
Insulin Levemir | Phase 3 | Diabetes Mellitus, Type 1 | - | - |
Bamlanivimab | Phase 3 | COVID-19 | - | - |
Mirikizumab IV | Phase 3 | Ulcerative Colitis | - | - |
Olaratumab | Phase 3 | Metastatic Pancreatic Cancer | - | - |
Pirtobrutinib | Phase 3 | Lymphoma, Non-Hodgkin | - | - |
Olanzapine Hydrochloride | Phase 3 | Bipolar Disorder | - | - |
Other standard therapy for ADHD | Phase 3 | Attention Deficit Hyperactivity Disorder | - | - |
Linagliptin/Pioglitazone FDC | Phase 3 | Diabetes Mellitus, Type 2 | - | - |
Lepodisiran | Phase 3 | Atherosclerosis | - | - |
BI 10773 | Phase 3 | Diabetes Mellitus, Type 2 | - | - |
TAS 102 | Phase 3 | Colorectal Cancer | - | - |
Linagliptin | Phase 3 | Diabetes Mellitus, Type 2 | - | - |
Intracoronary infusion of enriched bone marrow-derived progenitor cells | Phase 3 | Myocardial Infarction | - | - |
Sulfonylureas | Phase 3 | Type 2 Diabetes Mellitus | - | - |
Docetaxel (Taxane) | Phase 3 | Non-Small-Cell Lung Carcinoma | - | - |
valproate | Phase 3 | Manic or Mixed Episode Associated With Bipolar I Disorder | - | - |
Insulin lispro 6 day reservoir in-use | Phase 3 | Diabetes Mellitus, Type 1 | - | - |
alpha-glucosidase inhibitor (a-GI) | Phase 3 | Type 2 Diabetes Mellitus | - | - |
Empagliflozin low dose qd | Phase 3 | Diabetes Mellitus, Type 2 | - | - |
Glinides | Phase 3 | Type 2 Diabetes Mellitus | - | - |
Empagliflozin low dose bid | Phase 3 | Diabetes Mellitus, Type 2 | - | - |
fibrinolytic therapy or combination reduced fibrinolytic therapy | Phase 3 | Myocardial Infarction | - | - |
Empagliflozin high dose qd | Phase 3 | Diabetes Mellitus, Type 2 | - | - |
Empagliflozin high dose bid | Phase 3 | Diabetes Mellitus, Type 2 | - | - |
Topical Corticosteroid (TCS) | Phase 3 | Atopic Dermatitis | - | - |
Empagliflozin + Linagliptin | Phase 3 | Diabetes Mellitus, Type 2 | - | - |
BI 10773 open label | Phase 3 | Diabetes Mellitus, Type 2 | - | - |
BI10773 | Phase 3 | Diabetes Mellitus, Type 2 | - | - |
Ixekizumab Prefilled Syringe | Phase 3 | Plaque Psoriasis | - | - |
Atomoxetine Hydrochloride | Phase 3 | Attention Deficit Hyperactivity Disorder | - | |
Erbitux (Cetuximab) | Phase 2 | Colorectal Neoplasms | - | - |
LY3295668 | Phase 2 | Neoplasms | - | - |
LY2523355 | Phase 2 | Metastatic Breast Cancer | - | - |
Sivelestat | Phase 2 | Respiratory Distress Syndrome, Adult | - | - |
Icrucumab | Phase 2 | Colon Cancer | - | - |
LY2140023 | Phase 2 | Schizophrenia | - | - |
LY3209590 | Phase 2 | Type 2 Diabetes Mellitus | - | - |
Empagliflozin low | Phase 2 | Diabetes Mellitus, Type 1 | - | - |
cetuximab (Erbitux ®) | Phase 2 | Head and Neck Cancer | - | - |
Herceptin | Phase 2 | Breast Cancer | - | - |
Enzastaurin Hydrochloride | Phase 2 | Breast Neoplasms | - | - |
Pemetrexed - Phase 1 | Phase 2 | Ovarian Cancer | - | - |
IMC-1121B (ramucirumab) | Phase 2 | Carcinoma, Non-Small-Cell Lung | - | - |
LY3041658 | Phase 2 | Hidradenitis Suppurativa | - | - |
Ipatasertib | Phase 2 | Endometrial Cancer | - | - |
LY4268989 | Phase 2 | Ulcerative Colitis | - | - |
LY4100511 | Phase 2 | Plaque Psoriasis | - | - |
Inavolisib | Phase 2 | Endometrial Cancer | - | - |
Pemetrexed - Before Protocol Amendment | Phase 2 | Non Small Cell Lung Cancer | - | - |
LY3016859 | Phase 2 | Osteoarthritis | - | - |
LY2484595 | Phase 2 | Dyslipidemia | - | - |
MORF-057 | Phase 2 | Inflammatory Bowel Diseases | - | - |
DC-806 | Phase 2 | Plaque Psoriasis | - | - |
Carboplatin, Pemetrexed and Bevacizumab | Phase 2 | Non Small Cell Lung Cancer | - | - |
Granulocyte colony-stimulating factor (G-CSF) | Phase 2 | Small Cell Lung Cancer | - | - |
Prexasertib | Phase 2 | Ovarian Cancer | - | - |
LY2409021 | Phase 2 | Diabetes Mellitus, Type 2 | - | - |
avastin | Phase 2 | Colorectal Cancer | - | - |
Hydroxychloroquine Sulfate | Phase 2 | Pancreatic Cancer | - | - |
LY3473329 | Phase 2 | Lipoprotein Disorder | - | - |
LY517717 | Phase 2 | Total Knee Replacement | - | - |
LY3857210 | Phase 2 | Diabetic Peripheral Neuropathic Pain | - | - |
LY2951742 | Phase 2 | Migraine Headache | - | - |
Enzyme-inducing antiepileptic drugs (EIAED) | Phase 2 | Recurrent Glioblastoma | - | - |
Cixutumumab | Phase 2 | Non-Small-Cell Lung Carcinoma | - | - |
Mitoxantrone | Phase 2 | Prostate Cancer | - | - |
Folate | Phase 2 | Non-small Cell Lung Cancer (NSCLC) | - | - |
LY4005130 | Phase 2 | Vitiligo | - | - |
Carboplatin (AUC 6) | Phase 2 | Carcinoma, Non-Small-Cell Lung | - | - |
LY4395089 | Phase 2 | Crohn Disease | - | - |
LY2189102 | Phase 2 | Arthritis, Rheumatoid | - | - |
Doxorubicin (Adriamycin) | Phase 2 | Hodgkin's Disease | - | - |
LY3451838 | Phase 2 | Migraine | - | - |
Taltz | Phase 2 | Idiopathic Subglottic Stenosis | - | - |
Non-enzyme inducing antiepileptic drugs (NEIAED) | Phase 2 | Recurrent Glioblastoma | - | - |
LY2422347 | Phase 2 | Sleep Initiation and Maintenance Disorders | - | - |
Platinol | Phase 2 | Carcinoma, Transitional Cell | - | - |
LY4065967 | Phase 2 | Diabetic Peripheral Neuropathic Pain | - | - |
LY2623091 | Phase 2 | Primary Hypertension | - | - |
LY3938577 | Phase 2 | Diabetes Mellitus, Type 2 | - | - |
Mirikizumab - Intravenous (IV) | Phase 2 | Crohn Disease | - | - |
LY2428757 | Phase 2 | Diabetes Mellitus, Type 2 | - | - |
LOXO-292 | Phase 2 | Medullary Thyroid Cancer | - | - |
Tadalafil- Tablet or Oral suspension | Phase 2 | Pulmonary Arterial Hypertension | - | - |
LY3023414 | Phase 2 | Prostate Cancer Metastatic | - | - |
Pemetrexed - After Protocol Amendment | Phase 2 | Non Small Cell Lung Cancer | - | - |
Enzastaurin HCL | Phase 2 | Non-Small-Cell Lung Carcinoma | - | - |
IMC-A12 | Phase 2 | Prostate Cancer | - | - |
Mirikizumab - Subcutaneous (SC) | Phase 2 | Crohn Disease | - | - |
LY3561774 | Phase 2 | Dyslipidemias | - | - |
LY3848575 | Phase 2 | Neuropathic Pain | - | - |
Mevidalen | Phase 2 | Alzheimer Disease | - | - |
ALIMTA | Phase 2 | Colorectal Cancer | - | - |
Bimagrumab | Phase 2 | Obesity | - | - |
LY2603618 | Phase 2 | Non Small Cell Lung Cancer | - | - |
BI 10773 high dose | Phase 2 | Diabetes Mellitus, Type 2 | - | - |
LY2439821 | Phase 2 | Rheumatoid Arthritis | - | - |
human insulin inhalation powder (HIIP) | Phase 2 | Diabetes Mellitus, Type 1 | - | - |
LY3457263 | Phase 2 | Type 2 Diabetes | - | - |
Emibetuzumab | Phase 2 | Carcinoma, Non-Small-Cell Lung | - | - |
Testosterone | Phase 2 | Ejaculatory Dysfunction | - | - |
LY3214996 | Phase 2 | Pancreatic Cancer | - | - |
Solbinsiran | Phase 2 | Severe Hypertriglyceridemia | - | - |
Cetuximab + platinum + gemcitabine | Phase 2 | Non-Small-Cell Lung Carcinoma | - | - |
Prophylactic Loperamide | Phase 2 | Metastatic Breast Cancer | - | - |
Dinutuximab | Phase 2 | Relapsed Solid Tumor | - | - |
Ramucirumab DP | Phase 2 | Carcinoma of Urinary Tract | - | - |
LY451395 | Phase 2 | Alzheimer's Disease | - | - |
Cetuximab, Cisplatin, Doxorubicin & Cyclophosphamide | Phase 2 | Thymoma | - | - |
LY3016859 ISA | Phase 2 | Osteoarthritis, Knee | - | - |
LOXO-305 | Phase 2 | Leukemia, Lymphoid | - | - |
LY317615 | Phase 2 | Non-Hodgkin's Lymphoma | - | - |
LY2181308 sodium | Phase 2 | Prostate Cancer | - | - |
LY3819469 | Phase 2 | Lipoprotein Disorder | - | - |
LY686017 | Phase 2 | Social Phobia | - | - |
LY573636-sodium | Phase 2 | Ovarian Cancer | - | - |
Zagotenemab | Phase 2 | Alzheimer Disease (AD) | - | - |
Enzastaurin 500 milligram (mg) Once Daily (QD) | Phase 2 | Glioblastoma Multiforme | - | - |
STX-478 | Phase 2 | Breast Cancer | - | - |
naveglitazar | Phase 2 | Diabetes Mellitus, Non-Insulin-Dependent | - | - |
Mazdutide | Phase 2 | Alcohol Use Disorder | - | - |
Macupatide | Phase 2 | Obesity | - | - |
LY2452473 | Phase 2 | Erectile Dysfunction | - | - |
LY3305677 | Phase 2 | Obesity | - | - |
LY2875358 | Phase 2 | Carcinoma, Non-Small-Cell Lung | - | - |
LY450139 dihydrate | Phase 2 | Alzheimer's Disease | - | - |
Merestinib | Phase 2 | Biliary Tract Cancer | - | - |
Pemetrexed (Alimta) in combination with gemcitabine (Gemzar) | Phase 2 | Carcinoma, Non-Small-Cell Lung | - | - |
IMC-11F8 (necitumumab) | Phase 2 | Metastatic Colorectal Cancer | - | - |
U-500 insulin, 200 syringe units | Phase 2 | Type 2 Diabetes | - | - |
LY2196044 | Phase 2 | Alcohol Dependence | - | - |
LY3009104 | Phase 2 | Arthritis, Rheumatoid | - | - |
Drotrecogin alfa activated (Xigris) | Phase 2 | End Stage Renal Disease | - | - |
Baricitinib 4 milligram Oral Tablet | Phase 2 | Lichen Planus, Oral | - | - |
IMC-A12 (Cixutumumab) | Phase 2 | Adenocarcinoma of the Prostate | - | - |
LY2090314 | Phase 2 | Leukemia | - | - |
Eltrekibart | Phase 2 | Hidradenitis Suppurativa | - | - |
Lutetium Lu 177-PSMA-617 | Phase 2 | Castration-Resistant Prostate Carcinoma | - | - |
5FU/folinic acid | Phase 2 | Colorectal Cancer | - | - |
Empagliflozin medium | Phase 2 | Diabetes Mellitus, Type 1 | - | - |
LY3541860 | Phase 2 | Rheumatoid Arthritis | - | - |
5 - Fluorouracil | Phase 2 | Solid Tumor | - | - |
Leucovorin (LV) | Phase 2 | Colorectal Cancer | - | - |
Pemetrexed Phase 1 | Phase 2 | Non-Small Cell Lung Cancer | - | - |
LY3537021 | Phase 2 | Nausea | - | - |
Lutetium Lu-177 PNT2002 | Phase 2 | Oligometastatic Prostate Carcinoma | - | - |
LY3462817 | Phase 2 | Rheumatoid Arthritis | - | - |
Exenatide/min | Phase 2 | Euglycemia | - | - |
carboplatin and gemcitabine | Phase 2 | Non Small Cell Lung Cancer | - | - |
LY3015014 | Phase 2 | Hypercholesterolemia | - | - |
LY2624803 | Phase 2 | Primary Insomnia | - | - |
Vitamin B12 | Phase 2 | Non Small Cell Lung Cancer | - | - |
LY041001 (HIIP) | Phase 2 | Diabetes Mellitus, Type 2 | - | - |
IMC-A12 (cixutumumab) - 10 milligrams/kilogram (mg/kg) | Phase 2 | Hepatocellular Carcinoma | - | - |
Mibavademab | Phase 2 | Obesity | - | - |
LY3972406 | Phase 2 | Plaque Psoriasis | - | - |
LY3372689 | Phase 2 | Alzheimer Disease | - | - |
Selpercatinib Monotherapy | Phase 2 | Differentiated Thyroid Cancer | - | - |
Empagliflozin high | Phase 2 | Diabetes Mellitus, Type 1 | - | - |
Carboplatin - Phase 2 | Phase 2 | Ovarian Cancer | - | - |
LY3841136 | Phase 2 | Obesity | - | - |
Gemcitabine, Etoposide | Phase 2 | Pancreatic Cancer | - | - |
LY3039478 | Phase 2 | T-cell Acute Lymphoblastic Leukemia | - | - |
LY3437943 | Phase 2 | Obesity | - | - |
LY2510924 | Phase 2 | Extensive Stage Small Cell Lung Carcinoma | - | - |
ORX750 | Phase 2 | Narcolepsy Type 1 | - | - |
LY293111 | Phase 2 | Pancreatic Cancer | - | - |
LY2828360 | Phase 2 | Osteoarthritis, Knee | - | - |
LY3023703 | Phase 2 | Acute Pain | - | - |
pegfilgrastim | Phase 2 | Ovarian Cancer | - | - |
LY2189265 and Lifestyle Measures | Phase 2 | Diabetes Mellitus, Type 2 | - | - |
Cetuximab in combination with Carboplatin/Gemcitabine | Phase 2 | Stage IV Non-Small Cell Lung Cancer | - | - |
LY518674 | Phase 2 | Metabolic Syndrome X | - | - |
Prasugrel (CS-747) | Phase 2 | Cardiovascular Diseases | - | - |
sPLA2 Inhibitor | Phase 2 | Sepsis | - | - |
LY3526318 | Phase 2 | Chronic Low-back Pain | - | - |
Mazisotine | Phase 2 | Diabetic Peripheral Neuropathy | - | - |
LY2495655 | Phase 2 | Pancreatic Cancer | - | - |
U-500 insulin, 100 syringe units | Phase 2 | Type 2 Diabetes | - | - |
IMC-1121B | Phase 2 | Cancer | - | - |
Transdermal Teriparatide | Phase 2 | Osteoporosis | - | - |
Galcanezumab Prefilled Syringe | Phase 2 | Vestibular Migraine | - | - |
Carboplatin - Phase 1 | Phase 2 | Ovarian Cancer | - | - |
LY3202626 | Phase 2 | Alzheimer Disease | - | - |
IMC-18F1 | Phase 2 | Breast Cancer | - | - |
PPAR alpha | Phase 2 | Hypercholesterolemia | - | - |
5 - FU | Phase 2 | Solid Tumor | - | - |
Folinic acid (FA) | Phase 2 | Metastatic Colorectal Cancer | - | - |
gemcitabine, folinic acid, 5-FU | Phase 2 | Metastatic Pancreatic Cancer | - | - |
Buprenorphine | Phase 2 | Opioid Use Disorder | - | - |
LY3549492 | Phase 2 | Obesity | - | - |
LY3154207 | Phase 2 | Lewy Body Dementia | - | - |
Niraparib Tosylate Monohydrate | Phase 2 | Ovarian Cancer | - | - |
arzoxifene hydrochloride | Phase 2 | Endometrial Cancer | - | - |
Eplerenone | Phase 2 | Chronic Kidney Disease | - | - |
Triamcinolone (Optional) | Phase 2 | Atopic Dermatitis | - | - |
depot octreotide | Phase 2 | Carcinoma | - | - |
Subcutaneous Teriparatide | Phase 2 | Osteoporosis | - | - |
LY3556050 | Phase 2 | Diabetic Peripheral Neuropathy | - | - |
Pemetrexed - Phase 2 | Phase 2 | Ovarian Cancer | - | - |
ALIMTA plus Epirubicin | Phase 2 | Breast Cancer | - | - |
Fulvestrant Run-In | Phase 2 | ER-Positive Breast Cancer | - | - |
LY3871801 | Phase 2 | Rheumatoid Arthritis | - | - |
LY2157299 | Phase 2 | Hepatocellular Carcinoma | - | - |
LY2181308 | Phase 2 | Non-small Cell Lung Cancer | - | - |
tasisulam | Phase 2 | Metastatic Melanoma | - | - |
Giredestrant | Phase 2 | Endometrial Cancer | - | - |
LY2784544 | Phase 2 | Neoplasms, Hematologic | - | - |
LY3502970 | Phase 2 | Obesity | - | - |
LY2541546 | Phase 2 | Osteoporosis | - | - |
S-1 | Phase 2 | Metastatic Gastric Adenocarcinoma | - | - |
LY2228820 | Phase 2 | Epithelial Ovarian Cancer | - | - |
mitomycin C | Phase 2 | Superficial Bladder Cancer | - | - |
empagliflozin low dose | Phase 2 | Diabetes Mellitus, Type 1 | - | - |
LY545694 | Phase 2 | Osteoarthritis Knee Pain | - | - |
empagliflozin medium dose | Phase 2 | Diabetes Mellitus, Type 1 | - | - |
Brexucabtagene Autoleucel | Phase 2 | Mantle Cell Lymphoma | - | - |
empagliflozin high dose | Phase 2 | Diabetes Mellitus, Type 1 | - | - |
Platinum + Gemcitabine | Phase 2 | Non-Small-Cell Lung Carcinoma | - | - |
Radiation | Phase 2 | Glioma | - | - |
Diabetes Mellitus, Type 2
6 drugs in this indication
Type 2 Diabetes Mellitus
5 drugs in this indication
Type 2 Diabetes
5 drugs in this indication
Obesity
5 drugs in this indication
Alzheimer's disease
4 drugs in this indication
Psoriasis
3 drugs in this indication
Type 1 Diabetes Mellitus
3 drugs in this indication
diabetes
3 drugs in this indication
Non-Small-Cell Lung Carcinoma
2 drugs in this indication
Attention Deficit Hyperactivity Disorder
2 drugs in this indication
Plaque Psoriasis
2 drugs in this indication
Alzheimer's disease diagnostic
2 drugs in this indication
weight loss/obesity
2 drugs in this indication
Weight loss
2 drugs in this indication
reduce cardiovascular risk in adults with type 2 diabetes
2 drugs in this indication
Growth Disorder
1 drug in this indication
Benign Prostatic Hyperplasia
1 drug in this indication
Asthma
1 drug in this indication
Colorectal Neoplasms
1 drug in this indication
COVID-19
1 drug in this indication
Systemic Juvenile Idiopathic Arthritis
1 drug in this indication
Ovarian Cancer
1 drug in this indication
diabetes and obesity
1 drug in this indication
Pancreatic Neoplasms
1 drug in this indication
Overweight
1 drug in this indication
Sickle Cell Anemia
1 drug in this indication
Breast Cancer
1 drug in this indication
Schizophrenia
1 drug in this indication
Carcinoma, Non-Small-Cell Lung
1 drug in this indication
Major Depressive Disorder
1 drug in this indication
Total Knee Replacement
1 drug in this indication
Diabetic Peripheral Neuropathic Pain
1 drug in this indication
Metastatic Pancreatic Cancer
1 drug in this indication
Chronic Migraine
1 drug in this indication
Erectile Dysfunction
1 drug in this indication
Type 1 Diabetes
1 drug in this indication
Arthritis, Rheumatoid
1 drug in this indication
Neoplasms, Hematologic
1 drug in this indication
Lipoprotein Disorder
1 drug in this indication
Rheumatoid Arthritis
1 drug in this indication
Migraine
1 drug in this indication
Rare genetic forms of obesity
1 drug in this indication
treatment-resistant depression
1 drug in this indication
melanoma
1 drug in this indication
infectious disease
1 drug in this indication
Infectious diseases
1 drug in this indication
Osteoarthritis
1 drug in this indication
Inflammatory Bowel Diseases
1 drug in this indication
metastatic breast cancer
1 drug in this indication
cancer
1 drug in this indication
cardiometabolic
1 drug in this indication
Acute Pain
1 drug in this indication
Coronary Artery Disease
1 drug in this indication
previously untreated CLL/SLL
1 drug in this indication
Obesity, Type 2 Diabetes
1 drug in this indication
Previously untreated chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) in adult patients
1 drug in this indication
weight loss in people with heart disease
1 drug in this indication
obesity, type 2 diabetes, cardiovascular disease
1 drug in this indication
to lower the risk of heart attack, stroke or cardiovascular death in adults with type 2 diabetes
1 drug in this indication
cardiovascular risk reduction
1 drug in this indication
Metastatic Castration-Resistant Prostate Cancer
1 drug in this indication
autoimmune
1 drug in this indication
severe alopecia areata in pediatric patients 12 years of age and older
1 drug in this indication
reduce risk of major cardiovascular events
1 drug in this indication
diabetes, cardiometabolic conditions, leukemia
1 drug in this indication
Carcinoma, Transitional Cell
1 drug in this indication
type 2 diabetes in adults
1 drug in this indication
alopecia (children 12 and up)
1 drug in this indication
Breast Neoplasms
1 drug in this indication
Substance and psychiatric disorders
1 drug in this indication
Primary Hypertension
1 drug in this indication
Pulmonary Arterial Hypertension
1 drug in this indication
Prostate Cancer Metastatic
1 drug in this indication
Carcinoma, Small Cell Lung
1 drug in this indication
Atopic Dermatitis
1 drug in this indication
Genital Neoplasms, Female
1 drug in this indication
Medullary Thyroid Cancer
1 drug in this indication
ulcerative colitis, Crohn's disease
1 drug in this indication
Ulcerative colitis and Crohn's disease
1 drug in this indication
Platinum-sensitive ovarian cancer (FRα-targeting ADC, in combination with bevacizumab)
1 drug in this indication
Osteoporosis, Postmenopausal
1 drug in this indication
Recurrent Glioblastoma
1 drug in this indication
RET-altered metastatic thyroid cancer or solid tumors in pediatric patients two years of age and older
1 drug in this indication
Obesity-related heart failure
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in Eli Lilly and Company's drug pipeline?→
CatalystAlert tracks 384 drug candidates in Eli Lilly and Company's (LLY) pipeline across Phase 3, Phase 2. Its lead program is Abemaciclib (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Eli Lilly and Company's next FDA catalyst?→
Eli Lilly and Company's (LLY) next tracked catalyst is a Phase 2 readout expected December 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track LLY biotech catalysts?→
Add LLY to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Eli Lilly and Company's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.
